192 lines
81 KiB
Text
192 lines
81 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK609095">
|
|
<meta name="ncbi_domain" content="statpearls">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK609095/?report=reader">
|
|
<meta name="ncbi_pagename" content="Kell Blood Group System - StatPearls - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Kell Blood Group System - StatPearls - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="StatPearls [Internet]">
|
|
<meta name="citation_title" content="Kell Blood Group System">
|
|
<meta name="citation_publisher" content="StatPearls Publishing">
|
|
<meta name="citation_date" content="2024/10/28">
|
|
<meta name="citation_author" content="Ashish Maheshwari">
|
|
<meta name="citation_author" content="Muhammad Zubair">
|
|
<meta name="citation_author" content="Apoorva Maheshwari">
|
|
<meta name="citation_pmid" content="39536149">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK609095/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Kell Blood Group System">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="StatPearls Publishing">
|
|
<meta name="DC.Contributor" content="Ashish Maheshwari">
|
|
<meta name="DC.Contributor" content="Muhammad Zubair">
|
|
<meta name="DC.Contributor" content="Apoorva Maheshwari">
|
|
<meta name="DC.Date" content="2024/10/28">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK609095/">
|
|
<meta name="description" content='The Kell blood group system is vast, with 38 blood group antigens.[1] The Kell system is notorious for its immunogenicity, which is third after ABO and Rhesus D.[2] This system is involved in severe forms of hemolytic disease of the fetus and newborn and hemolytic transfusion reactions. Further, this blood group system is associated with chronic granulomatous diseases and a multisystem syndrome involving neurological, cardiovascular, and hematologic symptoms called McLeod syndrome.[3] The symbol of the Kell blood group system as per "International Society of Blood Transfusion" (ISBT) is KEL; ISBT number: 006.'>
|
|
<meta name="og:title" content="Kell Blood Group System">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content='The Kell blood group system is vast, with 38 blood group antigens.[1] The Kell system is notorious for its immunogenicity, which is third after ABO and Rhesus D.[2] This system is involved in severe forms of hemolytic disease of the fetus and newborn and hemolytic transfusion reactions. Further, this blood group system is associated with chronic granulomatous diseases and a multisystem syndrome involving neurological, cardiovascular, and hematologic symptoms called McLeod syndrome.[3] The symbol of the Kell blood group system as per "International Society of Blood Transfusion" (ISBT) is KEL; ISBT number: 006.'>
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK609095/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/statpearls/article-142043/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK609095/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B9E847C9281D1000000000021001C.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK609095/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"></div><div class="body"><div class="t">Kell Blood Group System</div><div class="j">StatPearls [Internet]</div></div><div class="tail"></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK609095/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK609095/&text=Kell%20Blood%20Group%20System"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/statpearls/?report=reader">Title Information</a><a href="/books/n/statpearls/toc/?report=reader">Table of Contents Page</a><a href="#_NBK609095_">Kell Blood Group System</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK609095/?report=classic">Switch to classic view</a><a href="/books/NBK609095/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK609095%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B9E847C9281D1000000000021001C.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK609095_"><span class="title" itemprop="name">Kell Blood Group System</span></h1><p class="contribs">Maheshwari A, Zubair M, Maheshwari A.</p><p class="fm-aai"><a href="#_NBK609095_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="article-142043.s1"><h2 id="_article-142043_s1_">Continuing Education Activity</h2><p>The Kell blood group system is a collection of antigens found on red blood cells, erythroid cells, myeloid progenitor cells, and other tissues. These antigens are highly immunogenic, following only the ABO and Rhesus D systems in significance. The Kell system’s antigens, fully developed at birth, can provoke strong immune responses in transfusions and are implicated in hemolytic disease of the fetus and newborn, as well as McLeod syndrome. The Kell antigens are detected on fetal erythrocytes as early as 10 weeks gestation, highlighting the importance of early recognition and management in pregnancy and transfusion medicine.</p><p>In this course, participants gain an understanding of the functional and clinical role of the Kell blood group system, including its significance in transfusion reactions and fetal complications. Clinicians and nurses learn to recognize how immunohistological reactivities of the Kell system influence clinical outcomes and become proficient in interpreting laboratory results related to these antigens. Collaboration with an interprofessional team, including hematologists, obstetricians, and laboratory technologists, is emphasized to improve patient care, enhance diagnostic accuracy, and mitigate transfusions and hemolytic conditions risks.</p><p>
|
|
<b>Objectives:</b>
|
|
<ul><li class="half_rhythm"><div>Differentiate between the immunohematological reactions caused by Kell antigens and those from other blood group systems.</div></li><li class="half_rhythm"><div>Screen for Kell antibodies in pregnant individuals to prevent hemolytic disease of the fetus and newborn.</div></li><li class="half_rhythm"><div>Implement appropriate transfusion strategies in patients with Kell antigen-related complications.</div></li><li class="half_rhythm"><div>Collaborate with the interprofessional team, including laboratory personnel and transfusion specialists, to timely diagnose and manage Kell antigen-related complications.</div></li></ul>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=142043&utm_source=pubmed&utm_campaign=reviews&utm_content=142043" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</p></div><div id="article-142043.s2"><h2 id="_article-142043_s2_">Introduction</h2><p>The Kell blood group system is vast, with 38 blood group antigens.<a class="bibr" href="#article-142043.r1" rid="article-142043.r1">[1]</a> The Kell system is notorious for its immunogenicity, which is third after ABO and Rhesus D.<a class="bibr" href="#article-142043.r2" rid="article-142043.r2">[2]</a> This system is involved in severe forms of hemolytic disease of the fetus and newborn and hemolytic transfusion reactions. Further, this blood group system is associated with chronic granulomatous diseases and a multisystem syndrome involving neurological, cardiovascular, and hematologic symptoms called McLeod syndrome.<a class="bibr" href="#article-142043.r3" rid="article-142043.r3">[3]</a> The symbol of the Kell blood group system as per "International Society of Blood Transfusion" (ISBT) is KEL; ISBT number: 006.</p><p>
|
|
<b>History: </b>The Kell blood group system was described in 1946 and named after Mrs Kelleher, whose newborn child died of hemolytic disease of fetus and newborn (HDFN) due to an antibody against his red blood cells (RBCs). This antibody also reacted with her daughter's and husband's RBCs and was named anti-K. Later, its antithetical antigen k was discovered in 1949, and the null phenotype (K0) in 1957.<a class="bibr" href="#article-142043.r4" rid="article-142043.r4">[4]</a></p><p>
|
|
<b>Genetics: </b>The <i>KEL </i>gene encodes the Kell antigens and is located at chromosome 7q34, comprising 20 exons spanning 21.25 kb of genomic DNA. This gene is also known as Kell metallo-endopeptidase, ECE3, or <i>CD238</i>. Single nucleotide polymorphisms are responsible for multiple Kell antigens. Another important XK gene required for the expression of Kell antigen is present on the short arm of chromosome X (Xp21.1) and is responsible for forming the Kx antigen.<a class="bibr" href="#article-142043.r5" rid="article-142043.r5">[5]</a></p><p>
|
|
<b>Structure of Kell glycoprotein: </b>The <i>KEL</i> gene encodes the polymorphic Kell and para-Kell glycoproteins, structurally single-pass RBC membrane proteins, or type II glycoproteins. The N terminal is intracytoplasmic, and the C terminal is multi-folded, bound by disulfide bonds, and extracytoplasmic. They constitute around 732 amino acids; mutations in these lead to the formation of a multitude of Kell antigens.<a class="bibr" href="#article-142043.r6" rid="article-142043.r6">[6]</a> The Kell glycoprotein is covalently linked to the Kx protein via a single disulfide bond. This Kx antigen protein traverses the RBC membrane 10 times. The absence of Kx protein leads to McLeod syndrome.<a class="bibr" href="#article-142043.r7" rid="article-142043.r7">[7]</a> The Kell glycoproteins have been found to have a similar sequence as the neprilysin (M13) family of zinc endopeptidases and, hence, act like proteolytic enzymes. They share a pentameric sequence HEXXH, which is needed to add zinc and proteolytic activity. Kell preferentially cleaves big endothelin-3, converting it to the bioactive peptide endothelin-3. This potent vasoconstrictor peptide leads to vascular endothelial growth factor formation.<a class="bibr" href="#article-142043.r8" rid="article-142043.r8">[8]</a><a class="bibr" href="#article-142043.r9" rid="article-142043.r9">[9]</a></p><p>
|
|
<b>Antigens: </b>The Kell system is highly polymorphic, consisting of 38 different blood group antigens.<a class="bibr" href="#article-142043.r10" rid="article-142043.r10">[10]</a><a class="bibr" href="#article-142043.r11" rid="article-142043.r11">[11]</a> The Kell antigens are found on erythroid cells and progenitor myeloid cells and are also present in skeletal muscles and testes.<a class="bibr" href="#article-142043.r12" rid="article-142043.r12">[12]</a><a class="bibr" href="#article-142043.r13" rid="article-142043.r13">[13]</a></p><p>
|
|
<b>Common Kell Antigens</b>
|
|
</p><p>
|
|
<b>K antigen:</b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL1</div></li><li class="half_rhythm"><div>ISBT number: 006.001</div></li><li class="half_rhythm"><div>Low prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: k (KEL 2)</div></li><li class="half_rhythm"><div>Cord RBCs: Expressed</div></li></ul><p>The K antigen is detected on fetal RBCs as early as the tenth gestational week and is well-developed at birth. The KEL1 antigen is strongly immunogenic after the Rh blood group system. Study results have reported that every 1 out of 10 Kell antigen-negative individuals transfused with Kell antigen-positive donor red cells can develop anti-K antibodies after transfusion.</p><p>The K antigen is not denatured by the enzymes ficin and papain but is destroyed by combined trypsin and chymotrypsin. Additionally, dithiothreitol (DTT), 2-mercaptoethanol, 2-aminoethylisothiouronium bromide, and ZZAP (mixture of a sulfhydryl reagent [dithiothreitol] and a proteolytic enzyme [papain or ficin]) can also destroy the Kell antigen. DTT, a reducing agent, interferes with the disulfide bonds between amino acids essential for the structural integrity of specific proteins and maintaining the pentameric structure of immunoglobulin (Ig) M molecules. Treating RBCs with DTT can denature other blood group antigens, including Kell, Lutheran, Yt, John Milton Hagen (JMH), Landsteiner-Wiener (LW), Cromer, Indian, Dombrock, and Knops systems—potentially impacting the recognition of these antigens by their specific antibodies.</p><p>
|
|
<b>k (Cellano) antigen:</b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL2</div></li><li class="half_rhythm"><div>Formerly termed as Cellano</div></li><li class="half_rhythm"><div>ISBT number: 006.002</div></li><li class="half_rhythm"><div>High prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: K (KEL1)</div></li><li class="half_rhythm"><div>Cord RBCs: Expressed</div></li><li class="half_rhythm"><div>Detected as early as seven weeks of gestation.</div></li><li class="half_rhythm"><div>Resistance and sensitivity to enzymes and chemicals are the same as those of KEL1</div></li></ul><p>
|
|
<b>Kp<sup>a </sup>antigen: </b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL3</div></li><li class="half_rhythm"><div>ISBT number: 006.003</div></li><li class="half_rhythm"><div>Low prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: Kp<sup>b</sup> (KEL4) Kp<sup>c </sup>(KEL21)</div></li><li class="half_rhythm"><div>Cord RBCs: Expressed</div></li><li class="half_rhythm"><div>Resistant to enzymes (ficin, papain, chymotrypsin)</div></li></ul><p>
|
|
<b>Kp<sup>b </sup>antigen: </b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL4</div></li><li class="half_rhythm"><div>ISBT number: 006.004</div></li><li class="half_rhythm"><div>High prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: Kp<sup>a</sup> (KEL3) Kp<sup>c </sup>(KEL21)</div></li><li class="half_rhythm"><div>Cord RBC's: Expressed</div></li><li class="half_rhythm"><div>Resistant to enzymes (ficin, papain, chymotrypsin)</div></li></ul><p>
|
|
<b>Js<sup>a </sup>antigen:</b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL6</div></li><li class="half_rhythm"><div>ISBT number: 006.006</div></li><li class="half_rhythm"><div>Low prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: Js<sup>b</sup> (KEL7)</div></li><li class="half_rhythm"><div>Cord RBCs: Expressed</div></li><li class="half_rhythm"><div>Resistant to enzymes (ficin, papain, chymotrypsin)</div></li></ul><p>
|
|
<b>Js<sup>b </sup>antigen:</b>
|
|
</p><ul><li class="half_rhythm"><div>ISBT symbol: KEL7</div></li><li class="half_rhythm"><div>ISBT number: 006.007</div></li><li class="half_rhythm"><div>High prevalence antigen</div></li><li class="half_rhythm"><div>Antithetical antigen: Js<sup>a</sup> (KEL6)</div></li><li class="half_rhythm"><div>Cord RBC: Expressed</div></li><li class="half_rhythm"><div>Resistant to enzymes (ficin, papain, chymotrypsin)</div></li></ul><p>
|
|
<b>Other rare Kell antigens</b>
|
|
</p><p>These are further divided as high and low-prevalence antigens:</p><p>
|
|
<b>High prevalence antigens: </b>Ku (KEL5), KEL11, KEL12, KEL13, KEL14, KEL16, KEL18, KEL19, Km (KEL20), KEL22, TOU (KEL26), RAZ (KEL27), KALT (KEL29), KTIM (KEL30), KUCI (KEL32), KANT (KEL33), KASH (KEL34), KELP (KEL35), KETI (KEL36), KHUL(KEL37), KYOR(KEL38), KEL40</p><p>
|
|
<b>Low prevalence antigens: </b>Ula (KEL10), Wka (KEL17), KEL21, KEL23, KEL24, VLAN (KEL25), VONG (KEL28), KYO (KEL31), KEAL (KEL39), KEL41</p><p>
|
|
<b>Antibodies of the Kell Blood Group System</b>
|
|
</p><p>Anti-K antibodies, commonly IgG antibodies, do not bind complement and mostly react at 37 °C with the anti-human globulin (AHG) phase. Anti-K antibodies can also react at room temperature in the saline phase if they are IgM-type; they are usually formed in response to exposure following pregnancy or transfusion, but some examples of naturally occurring anti-K can also be seen. These IgM antibodies have been found in patients with <i>Escherichia coli</i> infections, which disappear after recovery.<a class="bibr" href="#article-142043.r14" rid="article-142043.r14">[14]</a></p><p>Anti-K antibodies may show depressed reactivity with some low–ionic-strength solution reagents, so an AHG phase is required to detect these antibodies.<a class="bibr" href="#article-142043.r15" rid="article-142043.r15">[15]</a> Anti-K has been implicated in severe hemolytic transfusion reactions and HDFN. If a patient develops antibodies to high-prevalence Kell antigens like k, it is challenging to find compatible units due to the low percentage of antigen-negative donors; antibody formation is rare due to its high prevalence.</p><p>Identifying antibodies against low-prevalence antigens is difficult as their corresponding antigens are not included in antibody identification panels, which can rarely present as unexpected HDFN or transfusion reactions (see <b>Table.</b> Kell Blood Group Frequencies in Different Populations by Percentage). Anti-K will react well with K+k+ and K+k− red cells in antibody panels, showing no dosage phenomena. A rare case report of anti-Js<sup>b</sup> was found in the Nigerian population, where this antibody was associated with decreased red cell survival.<a class="bibr" href="#article-142043.r16" rid="article-142043.r16">[16]</a> </p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figarticle142043table0"><a href="/books/NBK609095/table/article-142043.table0/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobarticle142043table0"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="article-142043.table0"><a href="/books/NBK609095/table/article-142043.table0/?report=objectonly" target="object" rid-ob="figobarticle142043table0">Table</a></h4><p class="float-caption no_bottom_margin">Table. Kell Blood Group Frequencies in Different Populations by Percentage. </p></div></div><p>
|
|
<b>Uncommon Kell Phenotypes</b>
|
|
</p><p>
|
|
<b>K0 phenotype and anti-Ku antibody: </b>K0 or Kell null phenotype was identified by Chown et al in 1957, and it lacks all Kell antigens on the RBCs. The Kell null phenotype shows a prevalence of 0.001% except in populations of Finland and Japan.<a class="bibr" href="#article-142043.r21" rid="article-142043.r21">[21]</a><a class="bibr" href="#article-142043.r22" rid="article-142043.r22">[22]</a> These individuals show the inheritance of 2 recessive K0 genes in homozygotes (K0 K0). The absent antigens do not cause any functional abnormality in these RBCs.<a class="bibr" href="#article-142043.r5" rid="article-142043.r5">[5]</a> The alloantibody in K0 individuals post-transfusion has been called anti-Ku (anti-KEL5), which is clinically significant.<a class="bibr" href="#article-142043.r23" rid="article-142043.r23">[23]</a> These recipients should only be transfused with the K0 red cell type. One case report shows that anti-Ku specificity and anti-H were also identified in co-trimoxazole (trimethoprim and sulfamethoxazole) dependent antibodies.<a class="bibr" href="#article-142043.r24" rid="article-142043.r24">[24]</a> If there is a diminished presence of Kell antigens in place of complete absence, the phenotype is called Kmod. This is due to multiple missense mutations in the glycoprotein. Both K0 and Kmod show increased Kx protein. Kmod individuals may also form anti-Ku-type antibodies, but neither are similar.<a class="bibr" href="#article-142043.r25" rid="article-142043.r25">[25]</a> </p><p>
|
|
<b>McLeod phenotype: </b>This rare phenotype occurs due to the absence of the Kx protein. Kell glycoprotein is covalently linked to Kx protein by a single disulfide bond, and hence, in its absence, it lacks a high prevalence Kell antigen and has depression of the rest. Individuals with this phenotype develop a neuromuscular syndrome, McLeod syndrome.<a class="bibr" href="#article-142043.r26" rid="article-142043.r26">[26]</a> This condition is an X-linked recessive disorder where females are carriers and males are affected. At the molecular level, it can be due to a hemizygous XK pathogenic variant (90%) or a hemizygous deletion of Xp21.1 (10%).<a class="bibr" href="#article-142043.r27" rid="article-142043.r27">[27]</a> The Kell blood group system antigens are expressed weakly in individuals with McLeod syndrome, except for the Km antigen (KEL20), which is absent. The <i>XK</i> gene encodes a protein that helps properly express antigens of the Kell blood group system on the RBC surface. When this gene is mutated, it leads to the functional ineffectiveness of the Kell antigens.<a class="bibr" href="#article-142043.r28" rid="article-142043.r28">[28]</a></p><p>
|
|
<b>Depressed Kell antigen (Cellano) in Gerbich-negative phenotypes: </b>Both Muller and Debien reported reduced expression of 'k' antigens in RBCs of Gerbich group-negative phenotype (Ge:-2,-3) in individuals using monoclonal anti-k. This may be due to conformational changes in epitopes of the Kell blood group system, which shift the protein 4.1 complex to proteins like glycophorin C in the RBC membrane.<a class="bibr" href="#article-142043.r29" rid="article-142043.r29">[29]</a><a class="bibr" href="#article-142043.r30" rid="article-142043.r30">[30]</a> </p><p>
|
|
<b>Lab method for Kell blood group determination</b>
|
|
</p><p>Determining the Kell blood group involves various methodologies, each with advantages and limitations. These methods can be broadly categorized into serological and molecular techniques.<a class="bibr" href="#article-142043.r31" rid="article-142043.r31">[31]</a> In serological methods, hemagglutination tests such as forward typing are commonly used to detect the presence of Kell antigens on RBCs by utilizing specific antibodies like anti-K. Agglutination indicates the presence of the K antigen, while a lack of agglutination suggests its absence. Although this method is rapid and straightforward, it may lack sensitivity for weakly expressed antigens, particularly in partial or weak Kell phenotypes.<a class="bibr" href="#article-142043.r32" rid="article-142043.r32">[32]</a> Reverse typing involves testing the serum for anti-K antibodies to confirm the results of forward typing, which is crucial for ensuring accurate blood typing before transfusions. This step helps identify any unexpected antibodies that could lead to transfusion reactions.<a class="bibr" href="#article-142043.r33" rid="article-142043.r33">[33]</a> Another technique, gel centrifugation, employs a gel medium to separate agglutinated from non-agglutinated cells, thereby improving sensitivity and specificity. This method is particularly beneficial in reducing false-negative results and is often used in blood banks for routine testing.<a class="bibr" href="#article-142043.r34" rid="article-142043.r34">[34]</a></p><p>In molecular methods, polymerase chain reaction (PCR)-based techniques are highly sensitive and detect specific genotypes associated with Kell antigens. This approach is particularly useful in cases where serological methods may fail, such as in patients with autoimmune hemolytic anemia or those who have been recently transfused, as these conditions can obscure antigen expression.<a class="bibr" href="#article-142043.r35" rid="article-142043.r35">[35]</a> PCR with sequence-specific primers (PCR-SSP) enables the determination of specific alleles associated with Kell antigens; this is both cost-effective and reliable, making it suitable for routine testing in blood banks. This method can also identify rare phenotypes that may not be detected through serological means.<a class="bibr" href="#article-142043.r36" rid="article-142043.r36">[36]</a> PCR with restriction fragment length polymorphism (PCR-RFLP) analyzes variations in DNA sequences corresponding to different Kell antigens, providing detailed genetic information about blood group polymorphisms. This level of detail can be crucial for understanding compatibility in transfusions and organ transplants.<a class="bibr" href="#article-142043.r37" rid="article-142043.r37">[37]</a><a class="bibr" href="#article-142043.r38" rid="article-142043.r38">[38]</a> Microarray technology, which can simultaneously analyze multiple blood group antigens, including Kell, is highly efficient for large-scale screenings and provides comprehensive data on various blood group systems. This method allows for rapid screening of donors and patients alike, facilitating better matching processes.<a class="bibr" href="#article-142043.r39" rid="article-142043.r39">[39]</a></p></div><div id="article-142043.s3"><h2 id="_article-142043_s3_">Clinical Significance</h2><p>
|
|
<b>Functional Role of Kell Blood Group System</b>: </p><ul><li class="half_rhythm"><div>RBC adhesion: Kell antigens are involved in RBC adhesion with vascular endothelium and act by cleaving endothelin-3.<a class="bibr" href="#article-142043.r8" rid="article-142043.r8">[8]</a></div></li><li class="half_rhythm"><div>RBC cell signaling: Results from recent studies show that recipient type-1 interferon production regulates RBC alloimmunization with Kel1 antigen.<a class="bibr" href="#article-142043.r40" rid="article-142043.r40">[40]</a></div></li><li class="half_rhythm"><div>Red cell structural integrity: All Kell blood group antigens and the Cartwright (Yta) antigen are completely denatured on treatment with DTT in the same concentration range, showing possible relation related to the disulfide bond integrity of the RBC membrane.<a class="bibr" href="#article-142043.r41" rid="article-142043.r41">[41]</a></div></li><li class="half_rhythm"><div>Erythroid lineage suppression: The presence of Kell antigens on erythroid precursors has been proven by suppression with anti-Kell antibodies on RBC production. These antibodies inhibit the colony-forming units and cause severe fetal anemia in the case of HDFN.<a class="bibr" href="#article-142043.r42" rid="article-142043.r42">[42]</a></div></li><li class="half_rhythm"><div>Role in platelet inhibition: Besides the erythroid series, Kell antigens are also on the megakaryocytic precursors. In the case of anti-Kell antibody formation, these antibodies inhibit the precursor cells and lead to thrombocytopenia.<a class="bibr" href="#article-142043.r43" rid="article-142043.r43">[43]</a><a class="bibr" href="#article-142043.r44" rid="article-142043.r44">[44]</a></div></li><li class="half_rhythm"><div>Association with gram-negative bacterial infection: IgM-type Kell antibodies have been identified in patients afflicted with <i>E coli</i> 0125:B15 enterocolitis.<a class="bibr" href="#article-142043.r14" rid="article-142043.r14">[14]</a><a class="bibr" href="#article-142043.r45" rid="article-142043.r45">[45]</a></div></li><li class="half_rhythm"><div>Association with mycobacterium: IgM-type naturally occurring anti-Kell antibodies have been identified in a previously non-sensitized individual suffering from pulmonary tuberculosis.<a class="bibr" href="#article-142043.r14" rid="article-142043.r14">[14]</a></div></li></ul><p>
|
|
<b>Kell Blood Group System and Disease Association</b>
|
|
</p><p>McLeod syndrome is an X-linked recessive disorder due to the absence of Kx protein, resulting in the loss of Kell antigen functions in red blood cells. Hematologically, it is characterized by irregular protrusions or acanthocytes on the red cell membrane, leading to decreased survival of RBCs and presenting with chronic, compensated hemolytic anemia. Patients with this condition also have several neuromuscular abnormalities termed McLeod neuro-acanthocytosis syndrome.</p><p>The neurological manifestation comprises movement disorders such as choreiform movements or facial tics and neuropsychiatric symptoms involving depression, anxiety, psychosis, obsessive-compulsive features, and cognitive dysfunction. These patients develop slow progressive muscular dystrophy, which starts in middle age and worsens with time. Cardiac symptoms include cardiomegaly, atrial fibrillation, and arrhythmia. Additionally, patients may also have seizures, dysarthria, dysphagia, and areflexia. There are increased creatinine kinase and carbonic anhydrase III levels in biochemical parameters.<a class="bibr" href="#article-142043.r46" rid="article-142043.r46">[46]</a></p><p>Chronic granulomatous disease and McLeod syndrome: Chronic granulomatous disease (CGD) is an X-linked disorder caused by mutations in <i>CYBB</i>, which encodes the nicotinamide adenine dinucleotide phosphate oxidase complex crucial for phagocytes to kill ingested pathogens. CGD is occasionally associated with McLeod syndrome due to contiguous gene deletion on the X chromosome.<a class="bibr" href="#article-142043.r47" rid="article-142043.r47">[47]</a></p><p>Hematological malignancies: In hematological malignancies, anti-Kell antibodies may be warm-type autoantibodies or naturally occurring alloantibodies against the Kell antigen.<a class="bibr" href="#article-142043.r48" rid="article-142043.r48">[48]</a><a class="bibr" href="#article-142043.r49" rid="article-142043.r49">[49]</a></p><p>HDFN and neonatal jaundice: Antibodies to the Kell system can cause severe HDFN and fetal death. These IgG antibodies destroy mature fetal RBCs and the erythroid precursor cells by inhibiting erythropoiesis. In the Kell blood group-related HDFN, the degree of anemia and bilirubin levels are unrelated to the severity of the disease.<a class="bibr" href="#article-142043.r50" rid="article-142043.r50">[50]</a><a class="bibr" href="#article-142043.r51" rid="article-142043.r51">[51]</a> A noninvasive prenatal test involving cell-free fetal DNA can be used for fetal antigen genotyping to diagnose HDFN.<a class="bibr" href="#article-142043.r52" rid="article-142043.r52">[52]</a></p><p>Transfusion: The Kell antigens are the most immunogenic, third only after ABO and Rhesus blood group systems. Antibodies to the Kell system are predominantly IgG and clinically significant. They are known to cause acute and delayed hemolytic transfusion reactions, which can be severe as well.<a class="bibr" href="#article-142043.r53" rid="article-142043.r53">[53]</a></p></div><div id="article-142043.s4"><h2 id="_article-142043_s4_">Enhancing Healthcare Team Outcomes </h2><p>Understanding the Kell blood group system is crucial for improving patient outcomes and equally important for clinical and laboratory clinicians. Continued research into the <i>KEL</i> gene and its associated protein is necessary across different diseases and to examine transfusion outcomes and clinical consequences. The nursing team must verify the availability of a Kell antigen-negative blood unit and the other mandatory pretransfusion checks when planning transfusions for patients with Kell antibodies.</p></div><div id="article-142043.s5"><h2 id="_article-142043_s5_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=142043&utm_source=pubmed&utm_campaign=reviews&utm_content=142043" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/articlelibrary/commentarticle/142043/?utm_source=pubmed&utm_campaign=comments&utm_content=142043" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
|
</div></li></ul></div><div id="article-142043.s6"><h2 id="_article-142043_s6_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="article-142043.r1">Lomas-Francis C, Vege S, Velliquette RW, Fuchisawa A, Uchikawa M, Tani Y, Moro H, Debnath AK, Westhoff CM. Expansion of the Kell blood group system: two new high-prevalence antigens and two novel K0 (Kellnull ) phenotypes. <span><span class="ref-journal">Transfusion. </span>2013 Nov;<span class="ref-vol">53</span>(11 Suppl 2):2887-91.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23968329" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23968329</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="article-142043.r2">Butler EA, Parikh R, Grandi SM, Ray JG, Cohen E. ABO and Rh blood groups and risk of infection: systematic review and meta-analysis. <span><span class="ref-journal">BMC Infect Dis. </span>2023 Nov 14;<span class="ref-vol">23</span>(1):797.</span> [<a href="/pmc/articles/PMC10647048/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10647048</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37964217" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37964217</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="article-142043.r3">Jung HH, Danek A, Frey BM. McLeod syndrome: a neurohaematological disorder. <span><span class="ref-journal">Vox Sang. </span>2007 Aug;<span class="ref-vol">93</span>(2):112-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17683354" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17683354</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="article-142043.r4">Daniels G. The molecular genetics of blood group polymorphism. <span><span class="ref-journal">Transpl Immunol. </span>2005 Aug;<span class="ref-vol">14</span>(3-4):143-53.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15982556" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15982556</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="article-142043.r5">Yu LC, Twu YC, Chang CY, Lin M. Molecular basis of the Kell-null phenotype: a mutation at the splice site of human KEL gene abolishes the expression of Kell blood group antigens. <span><span class="ref-journal">J Biol Chem. </span>2001 Mar 30;<span class="ref-vol">276</span>(13):10247-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11134029" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11134029</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="article-142043.r6">Mohandas N, Narla A. Blood group antigens in health and disease. <span><span class="ref-journal">Curr Opin Hematol. </span>2005 Mar;<span class="ref-vol">12</span>(2):135-40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15725904" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15725904</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="article-142043.r7">Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. <span><span class="ref-journal">Transfus Med Rev. </span>2000 Apr;<span class="ref-vol">14</span>(2):93-103.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10782495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10782495</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="article-142043.r8">Bland ND, Pinney JW, Thomas JE, Turner AJ, Isaac RE. Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships. <span><span class="ref-journal">BMC Evol Biol. </span>2008 Jan 23;<span class="ref-vol">8</span>:16.</span> [<a href="/pmc/articles/PMC2259306/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2259306</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18215274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18215274</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="article-142043.r9">Lee S, Debnath AK, Redman CM. Active amino acids of the Kell blood group protein and model of the ectodomain based on the structure of neutral endopeptidase 24.11. <span><span class="ref-journal">Blood. </span>2003 Oct 15;<span class="ref-vol">102</span>(8):3028-34.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12842980" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12842980</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="article-142043.r10">Ji Y, Veldhuisen B, Ligthart P, Haer-Wigman L, Jongerius J, Boujnan M, Ait Soussan A, Luo G, Fu Y, van der Schoot CE, de Haas M. Novel alleles at the Kell blood group locus that lead to Kell variant phenotype in the Dutch population. <span><span class="ref-journal">Transfusion. </span>2015 Feb;<span class="ref-vol">55</span>(2):413-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25156717" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25156717</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="article-142043.r11">Redman CM, Lee S. The Kell blood group system. <span><span class="ref-journal">Transfus Clin Biol. </span>1995;<span class="ref-vol">2</span>(4):243-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8542022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8542022</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="article-142043.r12">Wagner T, Berer A, Lanzer G, Geissler K. Kell is not restricted to the erythropoietic lineage but is also expressed on myeloid progenitor cells. <span><span class="ref-journal">Br J Haematol. </span>2000 Aug;<span class="ref-vol">110</span>(2):409-11.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10971399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10971399</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="article-142043.r13">Russo D, Wu X, Redman CM, Lee S. Expression of Kell blood group protein in nonerythroid tissues. <span><span class="ref-journal">Blood. </span>2000 Jul 01;<span class="ref-vol">96</span>(1):340-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10891471" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10891471</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="article-142043.r14">Marsh WL, Nichols ME, Oyen R, Thayer RS, Deere WL, Freed PJ, Schmelter SE. Naturally occurring anti-Kell stimulated by E. coli enterocolitis in a 20-day-old child. <span><span class="ref-journal">Transfusion. </span>1978 Mar-Apr;<span class="ref-vol">18</span>(2):149-54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/347643" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 347643</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="article-142043.r15">Molthan L, Strohm PL. Hemolytic transfusion reaction due to anti-Kell undetectable in low-ionic-strength solutions. <span><span class="ref-journal">Am J Clin Pathol. </span>1981 Apr;<span class="ref-vol">75</span>(4):629-31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7223723" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7223723</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="article-142043.r16">Yuan S, Ewing NP, Bailey D, Salvador M, Wang S. Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature. <span><span class="ref-journal">Immunohematology. </span>2007;<span class="ref-vol">23</span>(2):75-80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18004938" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18004938</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="article-142043.r17">Nanu A, Thapliyal RM. Blood group gene frequency in a selected north Indian population. <span><span class="ref-journal">Indian J Med Res. </span>1997 Sep;<span class="ref-vol">106</span>:242-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9378531" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9378531</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="article-142043.r18">Thakral B, Saluja K, Sharma RR, Marwaha N. Phenotype frequencies of blood group systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) in north Indian blood donors. <span><span class="ref-journal">Transfus Apher Sci. </span>2010 Aug;<span class="ref-vol">43</span>(1):17-22.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20558108" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20558108</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="article-142043.r19">Lin-Chu M, Broadberry RE, Chang FJ. The distribution of blood group antigens and alloantibodies among Chinese in Taiwan. <span><span class="ref-journal">Transfusion. </span>1988 Jul-Aug;<span class="ref-vol">28</span>(4):350-2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3133846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3133846</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="article-142043.r20">Abdelaal MA, Anyaegbu CC, al Sobhi EM, al Baz NM, Hodan K. Blood group phenotype distribution in Saudi Arabs. <span><span class="ref-journal">Afr J Med Med Sci. </span>1999 Sep-Dec;<span class="ref-vol">28</span>(3-4):133-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11205816" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11205816</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="article-142043.r21">CHOWN B, LEWIS M, KAITA K. A new Kell blood-group phenotype. <span><span class="ref-journal">Nature. </span>1957 Oct 05;<span class="ref-vol">180</span>(4588):711.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13477267" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13477267</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="article-142043.r22">Kim TY, Park MS, Jang JH, Woo HY, Cho D. Prevalence and molecular basis of null blood group phenotypes in the Korean population: Analysis using a public database. <span><span class="ref-journal">Transfusion. </span>2024 Jan;<span class="ref-vol">64</span>(1):19-23.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/38031501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38031501</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="article-142043.r23">Lin M, Wang CL, Chen FS, Ho LH. Fatal hemolytic transfusion reaction due to anti-Ku in a Knull patient. <span><span class="ref-journal">Immunohematology. </span>2003;<span class="ref-vol">19</span>(1):19-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15373542" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15373542</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="article-142043.r24">Pham BN, Gien D, Bensaad F, Babinet J, Dubeaux I, Rouger P, Le Pennec PY. Antibodies to co-trimoxazole (trimethoprim and/or sulfamethoxazole) related to the presence of the drug in a commercial low-ionic-strength solution. <span><span class="ref-journal">Transfusion. </span>2012 Apr;<span class="ref-vol">52</span>(4):844-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21910740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21910740</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="article-142043.r25">Lee S, Russo DC, Reid ME, Redman CM. Mutations that diminish expression of Kell surface protein and lead to the Kmod RBC phenotype. <span><span class="ref-journal">Transfusion. </span>2003 Aug;<span class="ref-vol">43</span>(8):1121-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12869119" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12869119</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="article-142043.r26">ALLEN FH, KRABBE SM, CORCORAN PA. A new phenotype (McLeod) in the Kell blood-group system. <span><span class="ref-journal">Vox Sang. </span>1961 Sep;<span class="ref-vol">6</span>:555-60.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13860532" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13860532</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="article-142043.r27">Bertelson CJ, Pogo AO, Chaudhuri A, Marsh WL, Redman CM, Banerjee D, Symmans WA, Simon T, Frey D, Kunkel LM. Localization of the McLeod locus (XK) within Xp21 by deletion analysis. <span><span class="ref-journal">Am J Hum Genet. </span>1988 May;<span class="ref-vol">42</span>(5):703-11.</span> [<a href="/pmc/articles/PMC1715185/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715185</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3358422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3358422</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="article-142043.r28">Marsh WL, Schnipper EF, Johnson CL, Mueller KA, Schwartz SA. An individual with McLeod syndrome and the Kell blood group antigen K(K1). <span><span class="ref-journal">Transfusion. </span>1983 Jul-Aug;<span class="ref-vol">23</span>(4):336-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6879675" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6879675</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="article-142043.r29">Salomao M, Zhang X, Yang Y, Lee S, Hartwig JH, Chasis JA, Mohandas N, An X. Protein 4.1R-dependent multiprotein complex: new insights into the structural organization of the red blood cell membrane. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008 Jun 10;<span class="ref-vol">105</span>(23):8026-31.</span> [<a href="/pmc/articles/PMC2430353/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2430353</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18524950" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18524950</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="article-142043.r30">Jaskiewicz E, Peyrard T, Kaczmarek R, Zerka A, Jodlowska M, Czerwinski M. The Gerbich blood group system: old knowledge, new importance. <span><span class="ref-journal">Transfus Med Rev. </span>2018 Apr;<span class="ref-vol">32</span>(2):111-116.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29540278" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29540278</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="article-142043.r31">Murphy MT, Fraser RH. Detection of Kell blood groups: molecular methods in the diagnostic laboratory. <span><span class="ref-journal">Blood Rev. </span>1997 Mar;<span class="ref-vol">11</span>(1):8-15.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9218102" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9218102</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="article-142043.r32">Li HY, Guo K. Blood Group Testing. <span><span class="ref-journal">Front Med (Lausanne). </span>2022;<span class="ref-vol">9</span>:827619.</span> [<a href="/pmc/articles/PMC8873177/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8873177</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35223922" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35223922</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="article-142043.r33">Mujahid A, Dickert FL. Blood Group Typing: From Classical Strategies to the Application of Synthetic Antibodies Generated by Molecular Imprinting. <span><span class="ref-journal">Sensors (Basel). </span>2015 Dec 31;<span class="ref-vol">16</span>(1)</span> [<a href="/pmc/articles/PMC4732084/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4732084</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26729127" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26729127</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="article-142043.r34">Lapierre Y, Rigal D, Adam J, Josef D, Meyer F, Greber S, Drot C. The gel test: a new way to detect red cell antigen-antibody reactions. <span><span class="ref-journal">Transfusion. </span>1990 Feb;<span class="ref-vol">30</span>(2):109-13.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2305438" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2305438</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="article-142043.r35">Gorakshakar A, Gogri H, Ghosh K. Evolution of technology for molecular genotyping in blood group systems. <span><span class="ref-journal">Indian J Med Res. </span>2017 Sep;<span class="ref-vol">146</span>(3):305-315.</span> [<a href="/pmc/articles/PMC5793464/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5793464</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29355136" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29355136</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="article-142043.r36">Quirino MG, Colli CM, Macedo LC, Sell AM, Visentainer JEL. Methods for blood group antigens detection: cost-effectiveness analysis of phenotyping and genotyping. <span><span class="ref-journal">Hematol Transfus Cell Ther. </span>2019 Jan-Mar;<span class="ref-vol">41</span>(1):44-49.</span> [<a href="/pmc/articles/PMC6371408/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6371408</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30793104" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30793104</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="article-142043.r37">Sell AM, Visentainer JE. Blood grouping based on PCR methods and agarose gel electrophoresis. <span><span class="ref-journal">Methods Mol Biol. </span>2015;<span class="ref-vol">1310</span>:37-49.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26024624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26024624</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="article-142043.r38">Arnoni CP, Muniz JG, de Paula TA, Person RD, Gazito D, Baleotti W, Barreto JA, Castilho L, Latini FR. An easy and efficient strategy for KEL genotyping in a multiethnic population. <span><span class="ref-journal">Rev Bras Hematol Hemoter. </span>2013;<span class="ref-vol">35</span>(2):99-102.</span> [<a href="/pmc/articles/PMC3672118/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3672118</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23741186" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23741186</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="article-142043.r39">Paris S, Rigal D, Barlet V, Verdier M, Coudurier N, Bailly P, Brès JC. Flexible automated platform for blood group genotyping on DNA microarrays. <span><span class="ref-journal">J Mol Diagn. </span>2014 May;<span class="ref-vol">16</span>(3):335-42.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24726279" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24726279</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="article-142043.r40">Liu D, Gibb DR, Escamilla-Rivera V, Liu J, Santhanakrishnan M, Shi Z, Xu L, Eisenbarth SC, Hendrickson JE. Type 1 IFN signaling critically regulates influenza-induced alloimmunization to transfused KEL RBCs in a murine model. <span><span class="ref-journal">Transfusion. </span>2019 Oct;<span class="ref-vol">59</span>(10):3243-3252.</span> [<a href="/pmc/articles/PMC6785373/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6785373</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31403208" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31403208</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="article-142043.r41">Branch DR, Muensch HA, Sy Siok Hian AL, Petz LD. Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity. <span><span class="ref-journal">Br J Haematol. </span>1983 Aug;<span class="ref-vol">54</span>(4):573-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6871108" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6871108</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="article-142043.r42">Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. <span><span class="ref-journal">N Engl J Med. </span>1998 Mar 19;<span class="ref-vol">338</span>(12):798-803.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9504940" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9504940</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="article-142043.r43">Wagner T, Bernaschek G, Geissler K. Inhibition of megakaryopoiesis by Kell-related antibodies. <span><span class="ref-journal">N Engl J Med. </span>2000 Jul 06;<span class="ref-vol">343</span>(1):72.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10896554" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10896554</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="article-142043.r44">Wagner T, Lanzer G, Geissler K. Kell expression on myeloid progenitor cells. <span><span class="ref-journal">Leuk Lymphoma. </span>2002 Mar;<span class="ref-vol">43</span>(3):479-85.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12002749" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12002749</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="article-142043.r45">Savalonis JM, Kalish RI, Cummings EA, Ryan RW, Aloisi R. Kell blood group activity of gram-negative bacteria. <span><span class="ref-journal">Transfusion. </span>1988 May-Jun;<span class="ref-vol">28</span>(3):229-32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3368935" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3368935</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="article-142043.r46">Peikert K, Danek A. VPS13 Forum Proceedings: XK, XK-Related and VPS13 Proteins in Membrane Lipid Dynamics. <span><span class="ref-journal">Contact (Thousand Oaks). </span>2023 Jan-Dec;<span class="ref-vol">6</span>:25152564231156994.</span> [<a href="/pmc/articles/PMC10243564/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10243564</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37366410" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37366410</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="article-142043.r47">Kato K, Mayer DC, Singh S, Reid M, Miller LH. Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2005 Apr 12;<span class="ref-vol">102</span>(15):5552-7.</span> [<a href="/pmc/articles/PMC556269/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC556269</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15805191" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15805191</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="article-142043.r48">Mangwana S, Gangwar V. Anti Kp<sup>a</sup> alloantibody: Development of a rare alloantibody in a non-Hodgkin's lymphoma patient of Indian origin. <span><span class="ref-journal">Asian J Transfus Sci. </span>2018 Jan-Jun;<span class="ref-vol">12</span>(1):81-84.</span> [<a href="/pmc/articles/PMC5850705/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5850705</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29563682" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29563682</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="article-142043.r49">Mukumoto Y, Konishi H, Ito K, Seno T, Okubo Y. An example of naturally occurring anti-Kell (K1) in a Japanese male. <span><span class="ref-journal">Vox Sang. </span>1978;<span class="ref-vol">35</span>(4):275-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/695444" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 695444</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="article-142043.r50">de Jonge N, Martens JE, Milani AL, Krijnen JL, van Krimpen C, Ponjee GA. Haemolytic disease of the newborn due to anti-K antibodies. <span><span class="ref-journal">Eur J Obstet Gynecol Reprod Biol. </span>1996 Jul;<span class="ref-vol">67</span>(1):69-72.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8789754" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8789754</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="article-142043.r51">Bowman JM, Harman FA, Manning CR, Pollock JM. Erythroblastosis fetalis produced by anti-k. <span><span class="ref-journal">Vox Sang. </span>1989;<span class="ref-vol">56</span>(3):187-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2728396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2728396</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="article-142043.r52">Cro' F, Lapucci C, Vicari E, Salsi G, Rizzo N, Farina A. An innovative test for non-invasive Kell genotyping on circulating fetal DNA by means of the allelic discrimination of K1 and K2 antigens. <span><span class="ref-journal">Am J Reprod Immunol. </span>2016 Dec;<span class="ref-vol">76</span>(6):499-503.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27730708" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27730708</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="article-142043.r53">PESCHEL E, McINTOSH HD, BROWN IW, MURDAUGH HV. Acute tubular necrosis after transfusion reaction due to anti-Kell antibodies; report of a case and discussion of management. <span><span class="ref-journal">J Am Med Assoc. </span>1958 Aug 02;<span class="ref-vol">167</span>(14):1736-41.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13563174" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13563174</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Ashish Maheshwari declares no relevant financial relationships with ineligible companies.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Apoorva Maheshwari declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></dl></div></div></div><div class="fm-sec"><h2 id="_NBK609095_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Ashish Maheshwari</span><sup>1</sup>; <span itemprop="author">Muhammad Zubair</span><sup>2</sup>; <span itemprop="author">Apoorva Maheshwari</span><sup>3</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Institute of Liver and Biliary Sciences</div><div class="affiliation"><sup>2</sup> Pakistan Kidney & Liver Institute and Research Centre - PKLI</div><div class="affiliation"><sup>3</sup> ILBS HOSPITAL NEW DELHI INDIA</div><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">October 28, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
|
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
|
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
|
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
|
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
|
</p></div></div><h3>Publisher</h3><p><a href="https://www.statpearls.com/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">StatPearls Publishing</a>, Treasure Island (FL)</p><h3>NLM Citation</h3><p>Maheshwari A, Zubair M, Maheshwari A. Kell Blood Group System. [Updated 2024 Oct 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobarticle142043table0"><div id="article-142043.table0" class="table"><h3><span class="title">Table. Kell Blood Group Frequencies in Different Populations by Percentage</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK609095/table/article-142043.table0/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__article-142043.table0_lrgtbl__"><table style="margin-left: auto; margin-right: auto; height: 178px;" class="no_top_margin"><tbody><tr><td rowspan="1" colspan="1" style="width: 94.875px;vertical-align:top;">
|
|
<p><b>Phenotype</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 90.1736px;vertical-align:top;">
|
|
<p><b>Caucasian</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 53.8125px;vertical-align:top;">
|
|
<p><b>Black</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 57.3125px;vertical-align:top;">
|
|
<p><b>Arabic</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 66.6042px;vertical-align:top;">
|
|
<p><b>Indian</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 70.4375px;vertical-align:top;">
|
|
<p><b>Chinese</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 83.125px;vertical-align:top;">
|
|
<p><b>Japanese</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 78.6597px;vertical-align:top;">
|
|
<p><b>Brazilian</b></p>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="width: 94.875px;vertical-align:top;">
|
|
<p><b>K+k-</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 90.1736px;vertical-align:top;">
|
|
<p>9%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 53.8125px;vertical-align:top;">
|
|
<p>2%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 57.3125px;vertical-align:top;">
|
|
<p>20%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 66.6042px;vertical-align:top;">
|
|
<p>4%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 70.4375px;vertical-align:top;">
|
|
<p><0.1%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 83.125px;vertical-align:top;">
|
|
<p><0.1%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 78.6597px;vertical-align:top;">
|
|
<p>5%</p>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="width: 94.875px;vertical-align:top;">
|
|
<p><b>K-k+</b></p>
|
|
</td><td rowspan="1" colspan="1" style="width: 90.1736px;vertical-align:top;">
|
|
<p>99.8%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 53.8125px;vertical-align:top;">
|
|
<p>99.9%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 57.3125px;vertical-align:top;">
|
|
<p>99.1%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 66.6042px;vertical-align:top;">
|
|
<p>>99.9%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 70.4375px;vertical-align:top;">
|
|
<p>>99.9%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 83.125px;vertical-align:top;">
|
|
<p>>99.9%</p>
|
|
</td><td rowspan="1" colspan="1" style="width: 78.6597px;vertical-align:top;">
|
|
<p>99.9% <a class="bibr" href="#article-142043.r17" rid="article-142043.r17">[17]</a><a class="bibr" href="#article-142043.r18" rid="article-142043.r18">[18]</a><a class="bibr" href="#article-142043.r19" rid="article-142043.r19">[19]</a><a class="bibr" href="#article-142043.r20" rid="article-142043.r20">[20]</a></p>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|